Search Results - "PAVLI, P"

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease by Subramaniam, K., Fallon, K., Ruut, T., Lane, D., McKay, R., Shadbolt, B., Ang, S., Cook, M., Platten, J., Pavli, P., Taupin, D.

“…Summary Background Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein…”
Get full text

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors by Subramaniam, K., Tymms, K., Shadbolt, B., Pavli, P.

“…Background Musculoskeletal symptoms are the most common extra‐intestinal manifestation associated with inflammatory bowel disease (IBD). Spondyloarthritis…”
Get full text

Infliximab‐induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate by Subramaniam, K., Chitturi, S., Brown, M., Pavli, P.

Get full text

Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis by Kiely, C. J., Subramaniam, K., Platten, J., Pavli, P.

“…Biological therapy, particularly the anti‐tumour necrosis factor (TNF) antibodies, infliximab and adalimumab, are used for the maintenance of remission for…”
Get full text

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy by Subramaniam, K., Richardson, A., Dodd, J., Platten, J., Shadbolt, B., Pavli, P.

“…Background Anti‐tumour necrosis factor (TNF) agents are used as induction and maintenance therapy in ulcerative colitis (UC) refractory to standard therapy and…”
Get full text

Foot drop developing during infliximab therapy for inflammatory bowel disease by Subramaniam, K, Hughes, A, Pavli, P

Get full text

Advances in the management of inflammatory bowel disease by Grimpen, F., Pavli, P.

“…Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically…”
Get full text

Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications by Subramaniam, K., Cherian, M., Jain, S., Latimer, M., Corbett, M., D'Rozario, J., Pavli, P.

“…The setting of chronic immunosuppression in inflammatory bowel disease (IBD) may promote the proliferation of Epstein–Barr virus‐positive neoplastic clones. We…”
Get full text

Placental involvement by non-Hodgkin lymphoma in a Crohn disease patient on long-term thiopurine therapy by Chen, G., Crispin, P., Cherian, M., Dahlstrom, J. E., Sethna, F. F., Kaye, G., Pavli, P., Subramaniam, K.

“…We report the first published case of aggressive diffuse large B‐cell (non‐Hodgkin) lymphoma in a 35‐year‐old pregnant woman who had Crohn disease and was…”
Get full text

Glatiramer acetate induced hepatotoxicity by Subramaniam, K, Pavli, P, Llewellyn, H, Chitturi, S

“…Glatiramer acetate (Copaxone), a polypeptide has been approved for treating patients with active relapsing-remitting multiple sclerosis. We report the first…”
Get more information

Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? by Subramaniam, K., Yeung, D., Grimpen, F., Joseph, J., Fay, K., Buckland, M., Talaulikar, D., Elijah, J., Clarke, A. C., Pavli, P., Moore, J.

“…We present three cases of the rare hepatosplenic T‐cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without…”
Get full text

Should patients be screened for hereditary cancer syndromes before starting anti‐TNF‐α therapy? by Subramaniam, K., Tucker, K., Craft, P., Pavli, P.

Get full text

Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention by FISHER, L., FISHER, A., PAVLI, P., DAVIS, M.

“…Summary Background No specific preventive strategy exists for acute gastrointestinal haemorrhage in hip fracture patients. Aims To determine the effectiveness…”
Get full text

NOD2 mutations and Crohn’s disease: are Paneth cells and their antimicrobial peptides the link? by Grimm, M C, Pavli, P

“…Perhaps Paneth cell α-defensins present in high levels in the terminal ileum inactivate luminal bacteria taken up by Peyer's patches or colonic lymphoid…”
Get full text

Interleukin 8: cells of origin in inflammatory bowel disease by Grimm, M C, Elsbury, S K, Pavli, P, Doe, W F

“…Neutrophils are important cellular mediators in inflammatory bowel disease (IBD). Interleukin (IL)8, a powerful neutrophil chemoattractant, is found in…”
Get full text

CARD15/NOD2 Risk Alleles in the Development of Crohn's Disease in the Australian Population by Cavanaugh, J. A., Adams, K. E., Quak, E. J., Bryce, M. E., O'Callaghan, N. J., Rodgers, H. J., Magarry, G. R., Butler, W. J., Eaden, J. A., Roberts‐Thomson, I. C., Pavli, P., Wilson, S. R., Callen, D. F.

“…Summary We have previously reported strong evidence for linkage between IBD1 and Crohn's disease (CD) in Australian Crohn's disease families. Three risk…”
Get full text

Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa by Grimm, M C, Pullman, W E, Bennett, G M, Sullivan, P J, Pavli, P, Doe, W F

“…Alterations in phenotype and function of intestinal macrophages occur in inflammatory bowel disease (IBD) but it is unclear whether these changes result from…”
Get more information

The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene‐environment interaction by Pierik, Marie, Yang, Huiying, Barmada, Michael M., Cavanaugh, Juleen A., Annese, Vito, Brant, Steven R., Cho, Judy H., Duerr, Richard H., Hugot, Jean‐Pierre, McGovern, Dermot P., Paavola‐Sakki, Paulina, Radford‐Smith, Graham L., Pavli, P., Silverberg, Mark S., Schreiber, Stephan, Taylor, Kent D., Vlietinck, Robert

“…Background and Aims: The inflammatory bowel diseases (IBDs) Crohn's disease (CD) and ulcerative colitis are complex disorders with an important genetic…”
Get full text

Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice by Stevceva, L, Pavli, P, Husband, A, Ramsay, A, Doe, W F

“…The importance of IL-4 and its effects in inflammatory bowel disease (IBD) was studied using the dextran sulphate sodium-induced model of experimental colitis…”
Get full text

Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa—implications for pathogenesis by GRIMM, M. C., PAVLI, P., POL, E., DOE, W. F.

“…SUMMARY Lipopolysaccharide (LPS) is abundant in the intestinal lumen. CD14 is the receptor for the LPS‐LPS binding protein complex, and its presence on…”
Get full text